USPTO Examiner PETRASH HILARY ANN - Art Unit 1644

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19043567HUMANIZED ANTI-TISSUE FACTOR ANTIBODY, ANTIBODY-DRUG CONJUGATE PREPARED THEREFROM AND USE THEREOFFebruary 2025June 2025Allow400YesNo
19031443ENGINEERED DENDRITIC CELL AND USE THEREOFJanuary 2025December 2025Allow1120YesNo
18910550ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOFOctober 2024March 2025Allow610NoNo
18818412HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOFAugust 2024January 2026Allow1621YesNo
18785900COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERSJuly 2024January 2026Abandon1710NoNo
18664078BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024April 2025Allow1120YesNo
18620397BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMarch 2024February 2026Allow2310YesNo
18612088ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOFMarch 2024September 2024Allow610YesNo
18612866ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOFMarch 2024September 2024Allow610YesNo
18440860ANTI-CD28 X ANTI-PSMA ANTIBODIESFebruary 2024April 2025Allow1421NoNo
18543673CD28/OX40 BISPECIFIC ANTIBODIESDecember 2023May 2024Allow501YesNo
18510256Anti-cMet Antibody-Drug Conjugates and Uses ThereofNovember 2023May 2025Allow1841YesNo
18346130CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETINGJune 2023June 2024Allow1110NoNo
18320885ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOFMay 2023August 2025Allow2710NoNo
18140972ANTIBODIES AGAINST YKL-40 AND USES THEREOFApril 2023July 2025Allow2731YesNo
18149593BISPECIFIC SARS-COV-2 ANTIBODIES AND METHODS OF USEJanuary 2023September 2024Allow2121NoNo
18082695IL-23 Specific Antibodies for the Treatment of Systemic SclerosisDecember 2022May 2025Abandon2920NoYes
18062453PROTEINS BINDING NKG2D, CD16 AND 5T4December 2022April 2024Abandon1701NoNo
17986374Methods of Treating Crohn's Disease with Anti-IL23 Specific AntibodyNovember 2022December 2024Abandon2520NoYes
18053955ANTIBODY MOLECULES AND CONJUGATESNovember 2022April 2024Allow1711NoNo
18052174METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF BCMAXCD3 BISPECIFIC ANTIBODIESNovember 2022May 2024Allow1810NoNo
17938258Regulatory T Cells Expressing Chimeric Antigen Receptors and Uses in SynucleinopathiesOctober 2022December 2025Abandon3821NoNo
17937850METHOD FOR TREATING PD-L1 EXPRESSING CANCEROctober 2022April 2025Abandon3031NoNo
17935154ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERSSeptember 2022December 2025Abandon3840NoNo
17932039HUMAN MONOCARBOXYLATE TRANSPORTER 1 ANTIBODIES AND USES THEREOFSeptember 2022January 2024Allow1601YesNo
17929518METHODS OF TREATING CANCER AND TUMOR-RELATED WEIGHT LOSS AND CACHEXIASeptember 2022October 2024Abandon2501NoNo
17870593Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 InhibitionJuly 2022August 2025Allow3741NoNo
17825511GENERATION OF A NEW SITE-SPECIFIC MONOCLONAL ANTIBODY FOR TAU PROTEIN AND ITS USE AS A TOOL IN SPECIFIC BIOMARKERS FOR EARLY DETECTION OF NEURODEGENERATIVE DISEASES AND PATHOLOGIESMay 2022January 2025Allow3220YesNo
17712787METHOD FOR PREPARING T CELLS FOR ADOPTIVE T CELL THERAPYApril 2022October 2024Abandon3011NoNo
17633743ANTIBODY CHEMICALLY INDUCED DIMERIZERS (AbCID) AS MOLECULAR SWITCHES AND USES THEREOFFebruary 2022January 2026Abandon4811NoNo
17592012Antibodies for Botulinum NeurotoxinsFebruary 2022June 2025Allow4000YesNo
17627319DEPLETION REGIMES FOR ENGINEERED T-CELL OR NK-CELL THERAPYJanuary 2022October 2025Abandon4501NoNo
17555636ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERSDecember 2021June 2025Allow4230NoNo
17541837Antibodies for Botulinum NeurotoxinsDecember 2021July 2025Allow4310NoNo
17612549ANTI-CD38 ANTIBODY AND METHODS OF USE THEREOFNovember 2021September 2025Allow4611YesNo
17508673OPIOID ANTAGONISTS FOR USE IN PATIENTS USING CHIMERIC ANTIGEN RECEPTOR T AND NATURAL KILLER (NK) CELL THERAPYOctober 2021November 2025Abandon4850NoNo
17497069Immunomodulatory PeptidesOctober 2021January 2024Allow2711YesNo
17601354BISPECIFIC ANTIBODYOctober 2021February 2025Allow4010NoNo
17427780TCR FUSION PROTEIN AND CELL EXPRESSING TCR FUSION PROTEINAugust 2021May 2025Abandon4601NoNo
17425564MONOCLONAL ANTIBODIES AGAINST MHC-BOUND HUMAN DICKKOPF-1 PEPTIDES AND USES THEREOFJuly 2021January 2025Allow4211YesNo
17377922Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus InfectionJuly 2021June 2024Abandon3510NoNo
17374227NEURODEGENERATIVE DISORDERSJuly 2021July 2024Allow3611YesNo
17420967MODIFIED IMMUNE CELLS CO-EXPRESSING CHIMERIC ANTIGEN RECEPTOR AND IL-6 ANTAGONIST FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPYJuly 2021March 2026Abandon5621YesNo
17418271COMPOUNDS AND METHODS FOR TREATMENT OF HEAD AND NECK CANCERJune 2021April 2025Abandon4501NoNo
17311313METHODS FOR DETECTING ACUTE MYELOID LEUKEMIAJune 2021October 2025Abandon5321NoNo
17293258CD38 AND ICAM1 ANTIBODIES AND USES THEREOFMay 2021November 2025Allow5521NoNo
17293342PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND EITHER ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCERMay 2021January 2026Abandon5721NoNo
17290960NEDD9 IN PULMONARY VASCULAR THROMBOEMBOLIC DISEASEMay 2021October 2024Abandon4201NoNo
17290836HUMANIZED AND VARIANT TGF-BETA1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOFMay 2021August 2025Allow5121YesNo
17289448HUMAN ANTIBODIES TARGETING ZIKA VIRUS NS1, NS1 POLYPEPTIDES AND USES THEREOFApril 2021October 2025Abandon5421NoNo
17309115TUMOR CELL AGGREGATION INHIBITORS' FOR TREATING CANCERApril 2021August 2025Abandon5221NoNo
17288445HUMANIZED AND STABILIZED FC5 VARIANTS FOR ENHANCEMENT OF BLOOD BRAIN BARRIER TRANSPORTApril 2021September 2025Abandon5321YesNo
17283607COMBINATION OF A BIG-H3 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF SOLID TUMORApril 2021February 2026Abandon5830NoNo
17212424Methods of Treating Crohn's Disease with Anti-IL23 Specific AntibodyMarch 2021July 2024Allow3930YesNo
17277984NOVEL BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIESMarch 2021April 2024Allow3701YesNo
17277906DUAL ACTING CD1D IMMUNOGLOBULINMarch 2021August 2024Allow4101YesNo
17278259AN ANTI-OX40 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND THE PHARMACEUTICAL USEMarch 2021October 2024Allow4311YesNo
17275647Improved Anti-FLT3 Antigen Binding ProteinsMarch 2021November 2024Allow4421YesNo
17250734ANTIBODIES SPECIFIC FOR NTSR1 AND USES THEREOFFebruary 2021June 2024Abandon4001NoNo
17270405MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3February 2021July 2024Allow4001YesNo
17268925ANTIBODIES TO HUMAN ZNT8February 2021April 2024Allow3801YesNo
17175008ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOFFebruary 2021September 2025Allow5541YesNo
17264507ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERSJanuary 2021March 2024Allow3810NoNo
17162585ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B SHEDDING AND METHODS OF USEJanuary 2021March 2024Allow3811YesNo
16972298MODULATING ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSISDecember 2020November 2024Abandon4721NoNo
17054606PHARMACEUTICAL COMPOSITION COMPRISING CCN5 AS ACTIVE INGREDIENT, FOR PREVENTING OR TREATING RETINAL DISEASESNovember 2020March 2025Allow5230YesNo
17044493KIR3DL3 AS AN HHLA2 RECEPTOR, ANTI-HHLA2 ANTIBODIES, AND USES THEREOFOctober 2020June 2024Allow4411YesNo
16966232NERVE CELL CULTURE MATERIAL AND THERAPEUTIC AGENT FOR NERVE DAMAGEJuly 2020April 2024Abandon4410NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner PETRASH, HILARY ANN - Prosecution Strategy Guide

Executive Summary

Examiner PETRASH, HILARY ANN works in Art Unit 1644 and has examined 36 patent applications in our dataset. With an allowance rate of 58.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.

Allowance Patterns

Examiner PETRASH, HILARY ANN's allowance rate of 58.3% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PETRASH, HILARY ANN receive 1.47 office actions before reaching final disposition. This places the examiner in the 25% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PETRASH, HILARY ANN is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +61.1% benefit to allowance rate for applications examined by PETRASH, HILARY ANN. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 60.0% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.5% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.